Compare Plby Group Inc (PLBY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Viatris Inc — how do they compare? Plby Group Inc trades at $1.16 (market cap $138.38M), while Viatris Inc trades at $16.45 (market cap $18.95B). The key difference: Viatris Inc is far larger — about 136.9× Plby Group Inc's market cap, and Viatris Inc pays a 2.91% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| PLBY | VTRS | |
|---|---|---|
Market Cap | $138.38M | $18.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $17.86 |
52-Week Low | $1.11 | $9.49 |
Enterprise Value | $283.96M | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY trades at $1.18, up 0.85% with a bearish technical signal despite positive cash flow trends. The company shows improving fundamentals with revenue stabilizing around $120M and net losses narrowing significantly from -$278M in 2022 to -$13M in 2025. Recent Q2 2026 earnings beat expectations with a return to operating profitability, while analyst consensus remains strongly bullish with 75% buy ratings.
The outlook suggests cautious optimism as PLBY demonstrates operational turnaround with five consecutive quarters of positive EBITDA. Key risks include high debt levels and negative shareholder equity, but recent share repurchases and Russell index inclusion provide support. The stock faces resistance near current levels with technical indicators signaling caution.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
